|Other names||Δ1-Testosterone; 1-Dehydrotestosterone; RU-18761; Androsta-1,4-dien-17β-ol-3-one|
|AHFS/Drugs.com||International Drug Names|
|Drug class||Androgen; Anabolic steroid|
|Elimination half-life||Intramuscular: 14 days (as boldenone undecylenate)|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||286.415 g·mol−1|
|3D model (JSmol)|
|Melting point||165 °C (329 °F)|
|(what is this?)|
Boldenone (developmental code name RU-18761), is a naturally occurring anabolic–androgenic steroid (AAS) and the 1(2)-dehydrogenated analogue of testosterone. Boldenone itself has never been marketed; as a pharmaceutical drug, it is used as boldenone undecylenate, the undecylenate ester.
Like other AAS, boldenone is an agonist of the androgen receptor (AR). The activity of boldenone is mainly anabolic, with a low androgenic potency. Boldenone will increase nitrogen retention, protein synthesis, increases appetite and stimulates the release of erythropoietin in the kidneys. Boldenone was synthesized in an attempt to create a long-acting injectable metandienone, for androgen deficiency disorders. Boldenone acts similar to metandienone with fewer adverse androgenic effects.[medical citation needed] Although commonly compared to nandrolone, boldenone lacks progesterone receptor interaction and associated progestogenic side effects.
Boldenone, also known as Δ1-testosterone, 1-dehydrotestosterone, or androsta-1,4-dien-17β-ol-3-one, is a naturally occurring androstane steroid and a derivative of testosterone. It is specifically testosterone with a double bond between the C1 and C2 positions. A related compound is quinbolone, the 17-cyclopentenyl enol ether of boldenone.
Ciba reportedly patented boldenone in 1949. It subsequently developed several experimental esters of the drug in the 1950s and 1960s. One of these was boldenone undecylenate, which was introduced for clinical use under the brand name Parenabol and saw some use in the late 1960s and early 1970s. However, it was discontinued before the end of the 1970s. Subsequently, boldenone undecylenate was introduced by Squibb under the brand name Equipose for veterinary use, most commonly in horses.
Society and culture
Boldenone is marketed as veterinary drug as boldenone undecylenate (a derivative of boldenone) under the following brand names: Boldebal H, Equipoise, and Sybolin. It is marketed as a veterinary combination drug with methandriol under the brand name Drive.
Doping in sports
- Ruiz P, Strain EC (2011). Lowinson and Ruiz's Substance Abuse: A Comprehensive Textbook. Lippincott Williams & Wilkins. pp. 358–. ISBN 978-1-60547-277-5.
- Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 640–. ISBN 978-1-4757-2085-3.
- Index Nominum 2000: International Drug Directory. Taylor & Francis. 2000. pp. 131–. ISBN 978-3-88763-075-1.
- Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 52–. ISBN 978-94-011-4439-1.
- "Boldenone international brand names". Drugs.com. Retrieved 28 April 2017.
- Llewellyn W (2011). Anabolics. Molecular Nutrition Llc. pp. 483–490. ISBN 978-0-9828280-1-4.
- Forbes GB (June 1985). "The effect of anabolic steroids on lean body mass: the dose response curve". Metabolism: Clinical and Experimental. 34 (6): 571–3. doi:10.1016/0026-0495(85)90196-9. PMID 3999979.
- Lyka Labs. "Boldenol 200 (boldenone undecylenate)". Retrieved 15 January 2020.